Table 2.
Phenotypic and genetic features of GFAP+NNP and glioblastoma cell cultures
| Feature | GBM1 | GBM2 | GBM3 | GBM4 | GBM5 | GBM6 | GBM7 | GBM8 | NHA |
|---|---|---|---|---|---|---|---|---|---|
| % of multilineage phenotype cells in original culture | 95% | 70% | 63% | 45% | 30% | 10% | 15% | 45% | 100% |
| Other than multilineage phenotypes observed at the beginning of in vitro culture | glial, neuronal-intermediate, mesenchymal | glial, mesenchymal | glial, mesenchymal | glial, mesenchymal | glial, neuronal-intermediate, mesenchymal | glial, mesenchymal | other, not defined | glial, neuronal-intermediate, neuronal, mesenchymal | 0% |
| Clonable | - | + | - | + | - | + | - | - | - |
| % of CD133+ cells | 0% | 3% | 0% | 2% | 2% | 1% | 2% | 3% | 0% |
| Aggregate-forming ability | + | + | + | + | - | - | - | + | + |
| Aggregates stability | + | + | + | + | nt | nt | nt | + | - |
| Mesenchymal differentiation * | (+) 10 | (+) 15 | (+) 10 | (+) 15 | (+) 10 | (+) 10 | - | (+) 10 | (+)5 |
| Molecular background | EGFR+, P53wt | EGFR-, P53mut | EGFR+, P53wt | EGFR-, P53wt | EGFR+, P53wt | EGFR-, P53mut | EGFR-, P53 wt | EGFR-, P53mut | EGFR-, P53wt |
The phenotypes: multilineage phenotype, in brief CD44+/MAP2/GFAP+ (in detail Beta III tubulin+/Nestin+/Vimentin+/SOX2+); glial, GFAP+/CD44+/MAP2-; neuronal, MAP2+/GFAP-/CD44-; neuronal-intermediate, GFAP+/MAP2+/CD44-; mesenchymal, in brief CD44+/GFAP-/MAP2- (in detail CD44+/Vimentin+/Fibronectin+/GFAP-/MAP2-/Beta III-tubulin-/Nestin-/SOX2-).
EGFR+, amplification of EGFR gene; EGFR-, no amplification of EGFR gene; P53wt, wild type; P53mut, mutation in P53; nt, not tested.
GBM, glioblastoma
*Number of passages required to present only mesenchymal (non-neural) cells.